2005
DOI: 10.1620/tjem.207.59
|View full text |Cite
|
Sign up to set email alerts
|

High Frequency of Aspirin Resistance in Patients with Acute Coronary Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
33
0
5

Year Published

2006
2006
2016
2016

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 43 publications
(38 citation statements)
references
References 19 publications
0
33
0
5
Order By: Relevance
“…Medicaments that suppress inflammatory response to the damage, as recently described for trimetazidine (Kuralay et al 2006), could be of additional interest, while the use of aspirin known as an ti-in fl ammato r y d r u g th at h as anticoagulating and antioxidant features should be considered with care (Hobikoglu et al 2005). Therefore, novel bioengineered compounds should be tested as well as cocktails of classical antioxidants in order to reduce the reperfusion injury within the myocardium (Hung et al 2001), which may become efficient supportive treatments for myocardial recovery after AMI and successful convalescence of patients.…”
Section: Discussionmentioning
confidence: 99%
“…Medicaments that suppress inflammatory response to the damage, as recently described for trimetazidine (Kuralay et al 2006), could be of additional interest, while the use of aspirin known as an ti-in fl ammato r y d r u g th at h as anticoagulating and antioxidant features should be considered with care (Hobikoglu et al 2005). Therefore, novel bioengineered compounds should be tested as well as cocktails of classical antioxidants in order to reduce the reperfusion injury within the myocardium (Hung et al 2001), which may become efficient supportive treatments for myocardial recovery after AMI and successful convalescence of patients.…”
Section: Discussionmentioning
confidence: 99%
“…At these doses the anti-inflammatory effect of aspirin is generally considered negligible. However, the greatest benefit of low-dose aspirin use is the inhibition of platelet aggregation, which reduces cardiovascular events by modifying the thrombotic response to plaque rupture (Ridker et al 1997;Hannekens et al 1997;Hobikoglu et al 2005).…”
Section: Discussionmentioning
confidence: 99%
“…They found that incidence of aspirin resistance in patients with acute MI (in patients with all MI: 36%, in patients with STEMI: 64%, and in patients with NSTEMI: 28%) were higher than in patients with angina (21%) and chest pain of noncardiac origin (18%) and these results were similar to our results. In another study, Hobikoglu et al 12 showed that aspirin resistance is more prevalent in patients with ACS (40.3%) when compared with stable coronary artery disease patients (27%). Krasopoulos et al 9 showed that patients who were classified as aspirin resistant were at about a 4-fold increased risk of nonfatal and fatal cardiovascular,cerebrovascular, or vascular events while taking aspirin than their aspirin sensitive counterparts.…”
Section: Discussionmentioning
confidence: 96%
“…Similarly, previous studies demonstrated aspirin resistance is more common in patients with ACS and acute MI than in patients with stable coronary artery disease or patients with chest pain of noncardiac origin. 11,12 Recently in a systematic review article, Krasopoulos et al showed that E4 Clin. Cardiol.…”
Section: Discussionmentioning
confidence: 99%